These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26099427)

  • 61. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
    Mruthyunjaya P; Khalatbari D; Yang P; Stinnett S; Tano R; Ashton P; Guo H; Nazzaro M; Jaffe GJ
    Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
    [TBL] [Abstract][Full Text] [Related]  

  • 62. THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion.
    Ozkok A; Saleh OA; Sigford DK; Heroman JW; Schaal S
    Retina; 2015 Jul; 35(7):1393-400. PubMed ID: 25748280
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.
    Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA
    JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [New drugs in the treatment of noninfectious uveitis].
    Cano-Parra J; Díaz-Llopis M
    Arch Soc Esp Oftalmol; 2006 Dec; 81(12):671-3. PubMed ID: 17199159
    [No Abstract]   [Full Text] [Related]  

  • 66. IOP after triamcinolone acetonide.
    Lin JM; Tsai YY; Hung PT
    Ophthalmology; 2005 Dec; 112(12):2244; author reply 2244-5. PubMed ID: 16325726
    [No Abstract]   [Full Text] [Related]  

  • 67. Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection.
    Breusegem C; Vandewalle E; Van Calster J; Stalmans I; Zeyen T
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):573-6. PubMed ID: 18824737
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
    Soubrane G; Behar-Cohen F
    J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Subacromial triamcinolone acetonide, hyaluronic acid and saline injections for shoulder pain an RCT investigating the effectiveness in the first days.
    Penning LI; de Bie RA; Walenkamp GH
    BMC Musculoskelet Disord; 2014 Oct; 15():352. PubMed ID: 25341673
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Whole-genome sequencing unravels novel genetic determinants and regulatory pathways associated with triamcinolone acetonide-induced ocular hypertension.
    Badrinarayanan L; Nagarajan H; Rishi P; Rishi E; George RJ; Chitipothu S
    Mol Genet Genomics; 2023 Jan; 298(1):13-26. PubMed ID: 36222912
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.
    Gaballa SA; Kompella UB; Elgarhy O; Alqahtani AM; Pierscionek B; Alany RG; Abdelkader H
    Drug Deliv Transl Res; 2021 Jun; 11(3):866-893. PubMed ID: 32901367
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fluocinolone Implant Forceps: Instrument Modification for Enhanced Implant Insertion.
    Burke S; Albini TA; Silgado JD; Williams BK; Parel JM
    Int Ophthalmol Clin; 2016; 56(4):113-8. PubMed ID: 27575762
    [No Abstract]   [Full Text] [Related]  

  • 73. Side effects of corticosteroid injections: what's new?
    Berthelot JM; Le Goff B; Maugars Y
    Joint Bone Spine; 2013 Jul; 80(4):363-7. PubMed ID: 23352513
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Axial Length as a Risk Factor for Steroid-Induced Ocular Hypertension.
    Choi W; Kim JD; Bae HW; Kim CY; Seong GJ; Kim M
    Yonsei Med J; 2022 Sep; 63(9):850-855. PubMed ID: 36031785
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Research progress of ocular sustained-release corticosteroid delivery systems].
    Liu ZY; Chen YY
    Zhonghua Yan Ke Za Zhi; 2018 Feb; 54(2):154-160. PubMed ID: 29429302
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Short-acting Corticosteroid Injections Predict the Response to Fluocinolone Implant.
    Reddy AK; Patnaik JL; Pecen PE; Palestine AG
    Ophthalmol Retina; 2023 Aug; 7(8):739-741. PubMed ID: 37088244
    [No Abstract]   [Full Text] [Related]  

  • 77. Challenges and opportunities for drug delivery to the posterior of the eye.
    Cabrera FJ; Wang DC; Reddy K; Acharya G; Shin CS
    Drug Discov Today; 2019 Aug; 24(8):1679-1684. PubMed ID: 31175955
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Local subcutaneous atrophy after corticosteroid injection.
    Jacobs MB
    Postgrad Med; 1986 Sep; 80(4):159-60. PubMed ID: 3763512
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery.
    Battiston K; Parrag I; Statham M; Louka D; Fischer H; Mackey G; Daley A; Gu F; Baldwin E; Yang B; Muirhead B; Hicks EA; Sheardown H; Kalachev L; Crean C; Edelman J; Santerre JP; Naimark W
    Nat Commun; 2021 May; 12(1):2875. PubMed ID: 34001908
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [MIGS-off-label option for treatment-refractory steroid-induced ocular hypertension].
    Hohberger B; Haug M; Bergua A; Lämmer R
    Ophthalmologe; 2020 Jan; 117(1):62-65. PubMed ID: 31037408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.